Veliparib: a new therapeutic option in ovarian cancer?

被引：13

作者：

Ghisoni, Eleonora ^{[1
,2
]}

Giannone, Gaia ^{[1
,2
]}

Tuninetti, Valentina ^{[1
,2
]}

Genta, Sofia ^{[1
,2
]}

Scotto, Giulia ^{[1
,2
]}

Aglietta, Massimo ^{[1
,2
]}

Sangiolo, Dario ^{[1
,2
]}

Mittica, Gloria ^{[1
]}

Valabrega, Giorgio ^{[1
,2
]}

机构：

[1] IRCCS, Candiolo Canc Inst FPO, Str Prov 142 Km 3-95, I-10060 Turin, Italy

[2] Univ Torino, Dept Oncol, Turin, Italy

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 17期

关键词：

BRCA-mutated ovarian cancer; BRCA mutations; maintenance treatment; ovarian cancer; PARP inhibitors; poly (ADP-ribose) polymerase inhibitors; veliparib; POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; PAINFUL PERIPHERAL NEUROPATHY; PLATINUM-SENSITIVE OVARIAN; REFRACTORY SOLID TUMORS; DRUG-DRUG INTERACTIONS; GRADE SEROUS OVARIAN; PARP INHIBITOR; PHASE-I; FALLOPIAN-TUBE; PRIMARY PERITONEAL;

D O I：

10.2217/fon-2018-0883

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The role of poly ADP ribose polymerase inhibitors in ovarian cancer is rapidly evolving. Three different poly ADP ribose polymerase inhibitors (olaparib, niraparib and rucaparib) have been already approved as maintenance after response to platinum-based chemotherapy; two of them (olaparib and rucaparib) also as single agents. Veliparib, a novel PARPI, showed promising results in preclinical and early clinical settings. The aim of this review is to discuss veliparib's mechanisms of action, to provide a clinical update on its safety and activity in ovarian cancer, and to highlight future perspectives for its optimal use. Veliparib favorable toxicity profile encourages its use either as monotherapy or in combination. Its peculiar neuroprotective and radio-sensitizing effect warrant further investigation.

引用

页码：1975 / 1987

页数：13

共 81 条

[1] Inhibition of poly (ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models [J].

Albert, Jeffrey M. ;

Cao, Carolyn ;

Kim, Kwang Woon ;

Willey, Christopher D. ;

Geng, Ling ;

Xiao, Dakai ;

Wang, Hong ;

Sandler, Alan ;

Johnson, David H. ;

Colevas, Alexander D. ;

Low, Jennifer ;

Rothenberg, Mace L. ;

Lu, Bo .

CLINICAL CANCER RESEARCH, 2007, 13 (10) :3033-3042

[2]

[Anonymous], N ENGL J MED

[3]

[Anonymous], 2018, LYNP PACK INS

[4]

[Anonymous], 2014, LYNP PACK INS

[5]

[Anonymous], 2017, LYNP PACK INS

[6]

[Anonymous], ASCO ANN M P

[7]

Balko RA, 2018, AM J HOSP PALLIAT CA

[8] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[9]

BENJAMIN RC, 1980, J BIOL CHEM, V255, P493

[10] A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours [J].

Berlin, Jordan ;

Ramanathan, Ramesh K. ;

Strickler, John H. ;

Subramaniam, Deepa S. ;

Marshall, John ;

Kang, Yoon-Koo ;

Hetman, Robert ;

Dudley, Matthew W. ;

Zeng, Jiewei ;

Nickner, Caroline ;

Xiong, Hao ;

Komarnitsky, Philip ;

Shepherd, Stacie Peacock ;

Hurwitz, Herbert ;

Lenz, Heinz-Josef .

BRITISH JOURNAL OF CANCER, 2018, 118 (07) :938-946

← 1 2 3 4 5 6 7 8 9 →